Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Post by cool888on Dec 15, 2021 4:53am
335 Views
Post# 34231705

C-19 vaccines may be less effective against Omicron - WHO

C-19 vaccines may be less effective against Omicron - WHO

Article content

GENEVA — Preliminary evidence indicates that COVID-19 vaccines may be less effective against infection and transmission linked to the Omicron coronavirus variant, which also carries a higher risk of reinfection, the World Health Organization said on Wednesday.

The WHO, in its weekly epidemiological update, said that more data was needed to better understand the extent to which Omicron may evade immunity derived from either vaccines or previous infection.

“As a result of this, the overall risk related to the new variant of concern Omicron remains very high,” it said. (Reporting by Michael Shields; editing by Stephanie Nebehay)

<< Previous
Bullboard Posts
Next >>